DE69231221T2 - Gaba-rezeptor-modulatoren - Google Patents

Gaba-rezeptor-modulatoren

Info

Publication number
DE69231221T2
DE69231221T2 DE69231221T DE69231221T DE69231221T2 DE 69231221 T2 DE69231221 T2 DE 69231221T2 DE 69231221 T DE69231221 T DE 69231221T DE 69231221 T DE69231221 T DE 69231221T DE 69231221 T2 DE69231221 T2 DE 69231221T2
Authority
DE
Germany
Prior art keywords
receptor modulators
gaba receptor
insomnia
anxiety
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231221T
Other languages
English (en)
Other versions
DE69231221D1 (de
Inventor
Bruce Bolger
Wellman Gee
Tsai-Yun Lan
Delia Belelli
Syed Mirsadeghi
Hyde Purdy
Hasan Tahir
Ravindra B Upasani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE69231221D1 publication Critical patent/DE69231221D1/de
Application granted granted Critical
Publication of DE69231221T2 publication Critical patent/DE69231221T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69231221T 1991-08-13 1992-08-10 Gaba-rezeptor-modulatoren Expired - Lifetime DE69231221T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/745,216 US5232917A (en) 1987-08-25 1991-08-13 Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
PCT/US1992/006699 WO1993003732A1 (en) 1991-08-13 1992-08-10 Gaba receptor modulators

Publications (2)

Publication Number Publication Date
DE69231221D1 DE69231221D1 (de) 2000-08-10
DE69231221T2 true DE69231221T2 (de) 2000-11-09

Family

ID=24995739

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231221T Expired - Lifetime DE69231221T2 (de) 1991-08-13 1992-08-10 Gaba-rezeptor-modulatoren

Country Status (14)

Country Link
US (2) US5232917A (de)
EP (1) EP0554436B1 (de)
JP (1) JP3710470B2 (de)
KR (1) KR100287629B1 (de)
AT (1) ATE194287T1 (de)
AU (1) AU668880B2 (de)
CA (1) CA2093808C (de)
DE (1) DE69231221T2 (de)
DK (1) DK0554436T3 (de)
ES (1) ES2150917T3 (de)
GR (1) GR3034486T3 (de)
HK (1) HK1005986A1 (de)
NO (1) NO308252B1 (de)
WO (1) WO1993003732A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
DE69333352T2 (de) * 1993-06-15 2004-07-22 Pherin Corp., Menlo Park Androstansteroide als neurochemische initiatoren einer veränderung der hypothalamusfunktion beim menschen und verwandte pharmazeutische präparate und verfahren
NZ271363A (en) * 1993-08-04 1999-06-29 Akzo Nobel Nv Use of antiglucocorticoid steroids to treat anxiety disorders
HUT73855A (en) * 1993-10-27 1996-09-30 Merrell Pharma Inc Delta16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors, pharmaceutical compositions containing them and process for their production
CA2139549A1 (en) * 1994-01-28 1995-07-29 Kazumi Ogata Corticoid derivatives and pharmaceutical and cosmetic compositions
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5449795A (en) * 1994-02-14 1995-09-12 Cocensys, Inc. Process for synthesis of steroidal allylic tert. alcohols
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5994333A (en) * 1994-08-04 1999-11-30 Pherin Corporation Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
EP0808325B1 (de) * 1994-11-23 2001-01-17 Cocensys, Inc. Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
KR19990022323A (ko) * 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5912266A (en) * 1996-08-21 1999-06-15 American Home Products Corporation Beta2 integrin cell adhesion molecule inhibitors
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
DE69927960T2 (de) * 1998-03-11 2006-07-20 Torbjörn Backström Epiallopregnanolon zur behandlung von krankheiten des cns
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
RU2243232C2 (ru) * 1999-04-29 2004-12-27 Еро-Сельтик С.А. 3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE60020732T2 (de) * 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
GB9930562D0 (en) * 1999-12-23 2000-02-16 Boc Group Plc Partial oxidation of hydrogen sulphide
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20070014719A1 (en) * 2004-09-29 2007-01-18 Reading Christopher L Steroid analogs and characterization and treatment methods
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2664126C (en) 2006-11-21 2014-04-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
AU2008265898B2 (en) * 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
CA2716095C (en) 2008-02-26 2017-02-07 Emory University Steroid analogues for neuroprotection
GB2460350B (en) * 2008-04-25 2011-04-06 Kythera Biopharmaceuticals Inc Intermediates for the preparation of bile acids
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103819525A (zh) * 2008-05-20 2014-05-28 梅克芳股份公司 甾族化合物
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ2009521A3 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
EP2464653B1 (de) * 2009-08-13 2014-10-22 Marinus Pharmaceuticals, Inc. Verfahren zur herstellung von 3-hydroxy-3-methyl-5 -pregnan-20-on (ganaxolon)
CN102753181B (zh) 2010-01-14 2014-09-17 优麦克里尼穆德公司 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
CA2830984C (en) * 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
HUE031390T2 (en) 2011-05-20 2017-07-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale CB1 receptor antagonists
RU2665571C2 (ru) 2011-09-08 2018-08-31 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применения
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2766380B1 (de) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3-disubstituierte 19-nor-pregnan verbindungen, zusammensetzungen damit und verwendungen davon
PT2806877T (pt) 2012-01-23 2019-12-06 Sage Therapeutics Inc Formulações de esteroides neuroativos que compreendem um complexo de alopregnanolona e beta-ciclodextrinas de éter sulfobutílico
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
AU2013338043A1 (en) * 2012-10-29 2015-05-21 Allergan, Inc. Phosphate esters of bimatoprost and the prostamides
NZ708086A (en) 2012-11-28 2020-04-24 Inst Nat Sante Rech Med 3-(4’-substituted)-benzyl-ether derivatives of pregnenolone
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
SG10201706063UA (en) 2012-12-18 2017-09-28 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
US20160009755A1 (en) * 2013-03-01 2016-01-14 Revlon Consumer Products Corporation Cyrrhetinic alkyl esters and protected derivatives thereof
RS58166B1 (sr) 2013-03-13 2019-03-29 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
PT2986624T (pt) 2013-04-17 2020-07-07 Sage Therapeutics Inc Esteroides neuroativos 19-nor para métodos de tratamento
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
PT3498725T (pt) 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
CN105555277B (zh) 2013-07-19 2022-01-11 萨奇治疗股份有限公司 神经活性类固醇化合物、组合物及其用途
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
HUE050028T2 (hu) 2014-05-29 2021-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (de) 2014-09-02 2018-01-10 The Texas A&M University System Verfahren zur behandlung einer organophosphatvergiftung
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3280420B1 (de) 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
CN104926916B (zh) * 2015-06-05 2016-08-24 郑祖兰 甾体化合物，含其药物组合物及其制备方法和应用
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN113501855A (zh) 2015-07-06 2021-10-15 萨奇治疗股份有限公司 氧甾醇及其使用方法
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
CA3030420A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) * 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
EP4105223A1 (de) 2016-10-18 2022-12-21 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
IL266093B2 (en) 2016-10-18 2024-02-01 Sage Therapeutics Inc Oxysterols and methods of using them
BR112019015362A2 (pt) 2017-02-10 2020-10-20 Asarina Pharma Ab 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
JP7438956B2 (ja) * 2018-02-11 2024-02-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ステロイド系誘導体モジュレーター、その製造方法及び応用
EP3773599A1 (de) 2018-04-05 2021-02-17 Asarina Pharma ApS Gaba-a antagonisten zur behandlung von entzugsstörungen
US11542296B2 (en) 2018-04-23 2023-01-03 The Texas A&M University System Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
AU2019264032A1 (en) * 2018-05-04 2020-12-03 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
CN113301901B (zh) 2019-01-14 2022-09-09 北京轩义医药科技有限公司 四唑啉酮取代的类固醇及其用途
EP3712161A1 (de) * 2019-03-19 2020-09-23 Bionice, S.L.U. Verfahren zur herstellung eines hochreinen allopregnanolons und zwischenprodukten davon
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
JP2022543576A (ja) * 2019-08-07 2022-10-13 上▲海▼翰森生物医▲薬▼科技有限公司 ステロイド誘導体調節因子の塩及び結晶形態
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
DE1046039B (de) * 1957-09-07 1958-12-11 Schering Ag Verfahren zur Herstellung von Haloform-Anlagerungsprodukten der 3-Ketosteroide
US3061606A (en) * 1958-03-14 1962-10-30 Worcester Found Ex Biology Delta-4-pregnenolones and method
US3139445A (en) * 1958-05-23 1964-06-30 Schering Ag Haloform addition products of 17-formyl steroids
IT1051705B (it) * 1962-05-12 1981-05-20 Vismara Spa F Metodo per la preparazione di intermedi steroidali
US3132160A (en) * 1963-02-04 1964-05-05 Upjohn Co 3, 11-dioxygenated-17-desoxy-5beta-androstanes and processes therefor
US3385849A (en) * 1965-07-01 1968-05-28 Hoffmann La Roche Process for the preparation of 17beta-pregnanes from 17-oxo-steroids
GB1159434A (en) * 1965-08-16 1969-07-23 Glaxo Lab Ltd 11beta&;-Fluoro-19-nor-Steroids
US3665021A (en) * 1966-07-29 1972-05-23 Glaxo Lab Ltd 9alpha-unsubstituted-11beta-chloro-l9 nos-steroids
US3494943A (en) * 1967-12-29 1970-02-10 Rachelle Lab Inc Novel 9alpha-fluoro-11beta,17alpha,21-tri-hydroxy-16-hydroxymethyl - 6-(dihydroxy) methyl-1,4-pregnadiene-3,20-diones and derivatives thereof
US3637670A (en) * 1969-09-02 1972-01-25 Syntex Corp Intermediates and process for preparing useful 17alpha-hydroxy-20-keto and 17alpha 21-dihydroxy-20-keto pregnanes and derivatives thereof
CA895860A (en) * 1969-11-05 1972-03-21 Kruger Gunther PROCESS FOR THE PREPARATION OF 3.alpha.-HYDROXY-5.beta.-PREGNAN-20-ONE
US3816624A (en) * 1970-06-17 1974-06-11 Glaxo Lab Ltd Anaesthetic steroids
US3726864A (en) * 1970-07-20 1973-04-10 Glaxo Lab Ltd Novel 11 beta-chloro-19-norpregn-4-ene-3,20 diones and the 3,5-dienol ethers and esters thereof
GB1376892A (en) * 1970-11-12 1974-12-11 Glaxo Lab Ltd 2beta-substituted-3alpha-hydroxysteroids and their esters
GB1377608A (en) * 1970-12-17 1974-12-18 Glaxo Lab Ltd 3alpha-hydroxy or acyloxy pregnene-21-ethers
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3969345A (en) * 1970-12-17 1976-07-13 Glaxo Laboratories Limited 20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
DE2162555A1 (de) * 1970-12-17 1972-06-22 Glaxo Laboratories Ltd., Greenford, Middlesex (Grossbritannien) Anästhetisch wirkende Steroidverbindungen
GB1380248A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy steroids and esters thereof
US3900561A (en) * 1970-12-17 1975-08-19 Glaxo Lab Ltd Pharmaceutical compositions
US3763195A (en) * 1971-02-09 1973-10-02 Glaxo Lab Ltd Novel 21-acyloxy-3alpha-hydroxy-5alpha-pregnone-11,20-diones
CH563406A5 (de) * 1971-04-23 1975-06-30 Ciba Geigy Ag
US3875148A (en) * 1971-07-09 1975-04-01 Glaxo Lab Ltd 9{60 -unsubstituted-11{62 -bromo-19-norsteroids
US3825565A (en) * 1971-11-02 1974-07-23 Glaxo Lab Ltd 3alpha-hydroxy-delta4-steroids of the pregnane series and esters thereof
GB1409239A (en) * 1971-11-11 1975-10-08 Glaxo Lab Ltd Process for the preparation of 3alpha-hydroxy-5alpha-steroids
BE791196A (fr) * 1971-11-11 1973-05-10 Glaxo Lab Ltd Nouveaux steroides, leur procede de preparation et leurs applications
US3983111A (en) * 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3959260A (en) * 1972-05-05 1976-05-25 Glaxo Laboratories Limited Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
US3989686A (en) * 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
DE2438020A1 (de) * 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
DE2526373C2 (de) * 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) * 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4424218A (en) * 1979-08-17 1984-01-03 Roussel Uclaf Novel 3 α-amino steroids
DE2950026C2 (de) * 1979-12-10 1982-05-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 11-Ketosteroiden
US4360470A (en) * 1980-10-22 1982-11-23 Hoffmann-La Roche Inc. Process and intermediates for the synthesis of Vitamin D3 metabolites and chenodeoxycholic acid
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1989002272A1 (en) 1987-08-25 1989-03-23 Gee Kelvin W Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5371077A (en) * 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them

Also Published As

Publication number Publication date
CA2093808C (en) 2008-01-29
AU668880B2 (en) 1996-05-23
JPH06501962A (ja) 1994-03-03
DE69231221D1 (de) 2000-08-10
EP0554436A1 (de) 1993-08-11
US5232917A (en) 1993-08-03
GR3034486T3 (en) 2000-12-29
KR100287629B1 (ko) 2001-10-22
EP0554436B1 (de) 2000-07-05
NO931308L (no) 1993-06-14
ATE194287T1 (de) 2000-07-15
WO1993003732A1 (en) 1993-03-04
JP3710470B2 (ja) 2005-10-26
DK0554436T3 (da) 2000-09-18
EP0554436A4 (de) 1994-01-12
HK1005986A1 (en) 1999-02-05
CA2093808A1 (en) 1993-02-14
NO308252B1 (no) 2000-08-21
KR930702005A (ko) 1993-09-08
US5591733A (en) 1997-01-07
AU2471992A (en) 1993-03-16
NO931308D0 (no) 1993-04-06
ES2150917T3 (es) 2000-12-16

Similar Documents

Publication Publication Date Title
ATE194287T1 (de) Gaba-rezeptor-modulatoren
MX9703826A (es) Androstano y series del pregnano para la modulacion alosterica del receptor gaba.
JPS51149480A (en) Servo device for n umerical control
BE861914A (fr) Procede et dispositif pour accelerer le durcissement d'elements colles par des colles a durcissement cristallin
NO174531C (no) Festeinnretning for forsyn til en linerygg, samt apparat for påsetting av forsyn
JPS5390584A (en) Pre-heated fluid control method
JPS51116476A (en) Panel supplying apparatus for dwelling unit
JPS5413115A (en) Train service managing and controlling system
JPS52106089A (en) Management system for working process
IT1123580B (it) Dispositivo di regolazione per un tratto regolato,ad esempio un impianto di riscaldamento,comandato mediante due organi di impostazione parziali di una grandezza di impostazione complessiva
JPS5243080A (en) Numerical control system
JPS5259411A (en) Train operation controlling system
JPS51139214A (en) Bilateral catv system
JPS53120640A (en) Running control method for plating amount change in continuous electroplating line
JPS52102177A (en) Apparatus for automatically supplying feed stuff
JPS5315723A (en) Priority selection circuit
JPS5250653A (en) Input output handling device
JPS5366332A (en) Liquid crystal driving system
JPS5431243A (en) Clock control system
JPS5320702A (en) Telephone power supply system at disaster occurrence time
JPS5425671A (en) Burning and tightening unit for photo resist
JPS5279415A (en) Multistage synchronizing system
JPS51138672A (en) Process for prepari ng 4-benzoyl pyrazole derivatives
JPS53105946A (en) Transfer control system for time division data
JPS544459A (en) Nitration and denitration method

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 554436

Country of ref document: EP